Aadi says its solid tumor drug is unlikely to succeed, winding down the trial and axing staffers
Not even a year since it named Dave Lennon as CEO, Aadi Bioscience is facing major headwinds as it pulls back from a series of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
